Skip to content

Neobe Therapeutics Raises £5 Million to Help Cancer Treatments Break Through Tumour Barriers

Featured Replies

Neobe Therapeutics.avif

Stevenage-based biotechnology startup Neobe Therapeutics has raised £5 million in Seed funding to develop an unusual approach to cancer treatment: using engineered bacteria to help existing cancer drugs reach solid tumours.

The round was led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect, Empirical Ventures and returning pre-seed investor 2048 Ventures.

Founded in 2021 by Dr Pedro Correa de Sampaio and Annelise Soulier, Neobe is developing programmable bacterial therapies designed to address one of the challenges in treating solid tumours.

Using bacteria to make cancer treatments more effective

Some cancer treatments, including immunotherapies, have transformed patient care. However, they do not work for everyone.

One reason is the physical structure surrounding certain tumours. A dense, fibrous layer known as the tumour microenvironment can prevent drugs and immune cells from reaching cancer cells effectively.

Neobe is attempting to overcome this barrier by engineering harmless strains of common bacteria into programmable living medicines.

Once injected, the bacteria are designed to travel towards tumours and release enzymes that break down the surrounding tissue. The aim is to make the tumour more accessible to existing treatments, allowing drugs and immune cells to reach cancer cells more effectively.

The company's research has produced encouraging preclinical findings. In a 2026 study published in Molecular Cancer Therapeutics, Neobe worked with researchers from the University of Cyprus and Barts Cancer Institute in London. Its engineered bacteria helped an immunotherapy treatment produce complete tumour regression in one experimental model of triple-negative breast cancer.

These results are from preclinical research and do not yet demonstrate effectiveness in human patients.

Preparing for clinical development

The new funding will support the development of Neobe's lead programme, NEO22, through preclinical studies towards an investigational new drug filing in 2028.

The company has also appointed immuno-oncology specialist Dr Laura Chow as Chief Medical Officer to oversee its clinical development plans.

For investors, Neobe represents an opportunity in a growing area of biotechnology that combines synthetic biology with cancer research.

For founders, the round highlights how specialist scientific research can attract venture capital when it addresses a clearly defined problem and has a credible path towards clinical development.

Neobe still faces the significant challenges of demonstrating safety and effectiveness in human trials. However, this funding gives the company an opportunity to move its technology closer to that next milestone.


Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

Account

Navigation

Search

Search

Configure browser push notifications

Chrome (Android)
  1. Tap the lock icon next to the address bar.
  2. Tap Permissions → Notifications.
  3. Adjust your preference.
Chrome (Desktop)
  1. Click the padlock icon in the address bar.
  2. Select Site settings.
  3. Find Notifications and adjust your preference.